West Pharmaceutical Services, Inc. Stock News

Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 Aristocrats raising payouts in 2025 and an average growth rate of 5.14%, signaling continued income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return...

EXTON, Pa. , Aug. 21, 2025 /PRNewswire/ --  West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at multiple investor conferences in September.  Here are the details of the presentations: Wells Fargo 2025 Healthcare Conference: Fireside chat at 3:00 PM ET on Wednesday, September 3, 2025 i...

My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated future return of at least 10%, with 10 of these also appearing potentially undervalued by my Free Cash Flow model. Top highlighted stocks like MKTX, RACE, RMD, MSCI, and TTC combine strong free cash flo...

West Pharmaceutical Services, Inc.'s Q2 results signal a return to growth, driven by strong demand for high-value products and GLP-1 agonist components. I am revamping my bullish thesis: GLP-1 drugs now provide a powerful, sustained growth catalyst beyond the company's traditional biologics and injectable therapeutics exposure. Risks include elevated valuation, potential competition, and the th...

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of West Pharmaceutical Services, Inc. (NYSE: WST) breached their fiduciary duties to shareholders.

My estimations suggest that the U.S. government cuts to its healthcare system will not have a significant negative impact on West Pharmaceutical's revenues. In Q2 2025, the company's revenues increased by 9.17%, suggesting that the destocking effect is vanishing. The company has low debt levels, achieving a liabilities-to-assets ratio of 25.90% in Q2 2025. Additionally, it achieved a 17.03% net...

West Pharmaceutical Services, Inc. (NYSE:WST ) Q2 2025 Earnings Conference Call July 24, 2025 8:00 AM ET Company Participants Bernard J. Birkett - Senior VP & CFO Eric M.

West Pharmaceutical Services (WST 20.87%), a global manufacturer of drug packaging and delivery systems for the pharmaceutical and healthcare industries, reported Q2 2025 earnings on July 24, 2025. The key news was a significant beat on both GAAP revenue and non-GAAP EPS.